Soleno Therapeutics (SLNO) Cash & Current Investments (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Cash & Current Investments data on file, last reported at $255.6 million in Q1 2026.

• Quarterly Cash & Current Investments fell 11.84% year-over-year to $255.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $255.6 million (down 11.84% YoY) and the FY2025 annual result came in at $305.5 million, up 4.82% from the prior year.
• Cash & Current Investments retreated to $255.6 million in Q1 2026 per SLNO's latest filing, from $305.5 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $498.9 million in Q3 2025 and bottomed at $7.9 million in Q1 2023.
• The 5-year median for Cash & Current Investments is $169.7 million (2023), against an average of $172.8 million.
• The widest annual swing landed in 2023, when Cash & Current Investments slumped 72.76%; it then jumped 1793.67% in 2024.
• Tracing SLNO's Cash & Current Investments over 5 years: stood at $14.6 million in 2022, then soared by 1062.04% to $169.7 million in 2023, then soared by 71.76% to $291.4 million in 2024, then climbed by 4.82% to $305.5 million in 2025, then dropped by 16.33% to $255.6 million in 2026.
• Per Business Quant, the three latest SLNO Cash & Current Investments figures stand at $255.6 million (Q1 2026), $305.5 million (Q4 2025), and $498.9 million (Q3 2025).

Peer Comparison